Saturday, December 20, 2025 | 01:56 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 19 - Pharmaceutical

US FDA completes inspection of Strides Shasun's Bangalore facility

The company says the inspection was completed without issuance of Form 483, which is issued by US FDA for violations of good manufacturing practices

US FDA completes inspection of Strides Shasun's Bangalore facility
Updated On : 01 Jul 2016 | 1:53 PM IST

Sanofi, Boehringer Ingelheim ink animal health-consumer healthcare business swap pact

While Boehringer Ingelheim will transfer its CHC business to Sanofi, in return it will get Sanofi's animal health business Merial. In addition, Boehringer Ingelheim will pay Sanofi Euro 4.7 bn

Sanofi, Boehringer Ingelheim ink animal health-consumer healthcare business swap pact
Updated On : 28 Jun 2016 | 2:45 PM IST

RPG Life Sciences ties up Italian firm to foray into cosmetics

Through the tie-up with Labo Cosprophar, the Mumbai-based pharmaceutical company will launch two new products for hair and skin care

RPG Life Sciences ties up Italian firm to foray into cosmetics
Updated On : 28 Jun 2016 | 12:41 PM IST

Impact of Brexit to be majorly on drug and medical device regulation: Report

The European Medicines Agency (EMA), which is headquartered in the UK, is likely to be swiftly relocated to the EU, says GlobalData in a whitepaper

Impact of Brexit to be majorly on drug and medical device regulation: Report
Updated On : 27 Jun 2016 | 12:35 PM IST

DCGI grants permission for India's first siRNA drug trial

Biocon and the US-based Quark to start phase II/III study of a novel siRNA (small interfering RNA) drug candidate (QPI-1007) in rare eye disease in India

DCGI grants permission for India's first siRNA drug trial
Updated On : 23 Jun 2016 | 8:40 PM IST

Lupin receives US FDA nod for generic Activella tablet

Tablet is indicated in a woman with a uterus for treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis

Image
Updated On : 23 Jun 2016 | 8:37 PM IST

Introduce data protection as an IPR: Study

The Assocham-TechSci Research study also suggested for digitisation of IPR for pharmaceuticals in India to strengthen online processing

Introduce data protection as an IPR: Study
Updated On : 20 Jun 2016 | 3:17 PM IST

Cipla and Russia's Nacimbio join hands for HIV and hepatitis C drugs

As per the agreement, two sides will collaborate to set up a facility in Russia for the production of antiretroviral drugs

Cipla and Russia's Nacimbio join hands for HIV and hepatitis C drugs
Updated On : 20 Jun 2016 | 2:43 PM IST

Zydus Cadila partners with Eczacibasi to tap Turkish biosimilar market

As per the deal, Zydus will market biosimilars, which are currently unavailable in Turkey especially for the treatment of cancer

Zydus Cadila partners with Eczacibasi to tap Turkish biosimilar market
Updated On : 16 Jun 2016 | 3:09 PM IST

US specialty pharma firms to change their M&A strategies: Moody's

The slowdown in acquisitions, along with the scrutiny on aggressive price increases, will force many specialty pharmaceutical companies to shift their growth strategies, says the ratings agency

US specialty pharma firms to change their M&A strategies: Moody's
Updated On : 14 Jun 2016 | 12:47 PM IST

Gelatine capsules technically better than HPMC, says PHD Chamber to DCGI

The current annual installed capacity of HPMC is around 2 billion compared to gelatine's 120 billion, hence replacing HPMC with gelatine is not a feasible option

Gelatine capsules technically better than HPMC, says PHD Chamber to DCGI
Updated On : 13 Jun 2016 | 5:03 PM IST

Chaturbhuj Pharmaceutical to commercialise ayurvedic diabetes drug

The company has signed licensing agreement with National Research Development Corporation (NRDC) for Ayush-82, developed by Central Council for Research in Ayurvedic Sciences

Chaturbhuj Pharmaceutical to commercialise ayurvedic diabetes drug
Updated On : 13 Jun 2016 | 2:19 PM IST

Teva, Allergan agree to sell 8 products to Dr Reddy's for $350 mn

The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business

Teva, Allergan agree to sell 8 products to Dr Reddy's for $350 mn
Updated On : 13 Jun 2016 | 10:54 AM IST

Sun Pharma's OTC business forays into dermatology

The business, which current markets dietary supplements, analgesics and antacids, has rolled out Suncros, a sunscreen product

Image
Updated On : 09 Jun 2016 | 3:36 PM IST

Zydus Cadila to start phase 2 trials of saroglitazar for liver disease

The company has received US FDA approval to initiate phase 2 clinical trials of saroglitazar in patients with non-alcoholic steatohepatitis (NASH), a liver disease, in the US

Image
Updated On : 07 Jun 2016 | 2:27 PM IST

Eisai and Novartis to co-promote anticancer drugs in US

Two companies will promote Eisai's anticancer agent Lenvima in combination with everolimus as treatment for advanced renal cell carcinoma in the US

Image
Updated On : 07 Jun 2016 | 12:26 PM IST

Lupin receives US FDA's nod for antifungal drug voriconazole

The company has received approval for voriconazole tablet (50 mg & 200 mg) and oral suspension (40 mg/mL) - generic versions of PF Prism CV's Vfend tablet and oral suspension

Lupin receives US FDA's nod for antifungal drug voriconazole
Updated On : 06 Jun 2016 | 2:15 PM IST

Frontida BioPharm buys Sun Pharma's two US facilities

Sun Pharma has sold its two oral solid dosage manufacturing facilities located at Philadelphia and Aurora, along with 15 related products, to Frontida BioPharm

Frontida BioPharm buys Sun Pharma's two US facilities
Updated On : 06 Jun 2016 | 11:17 AM IST

Dr Reddy's launches psoriasis drug Sernivo in US

Sernivo (betamethasone dipropionate) spray is used for the treatment of mild to moderate plaque psoriasis

Image
Updated On : 04 Jun 2016 | 12:29 PM IST

Jubilant Biosys inks license pact with US-based Checkpoint for cancer drug

As per the deal, Jubilant Biosys will receive an upfront payment of $ 2 mn and contingent preclinical, clinical and regulatory payments including commercial milestones totalling up to $ 180 mn

Jubilant Biosys inks license pact with US-based Checkpoint for cancer drug
Updated On : 31 May 2016 | 2:52 PM IST